权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Reading Frame Correction for the Treatment of Batten Disease

阅读框架校正治疗 Batten 病

基本信息

批准号：
10597534
负责人：
Michelle L Hastings
金额：
$ 58.13万
依托单位：
ROSALIND FRANKLIN UNIV OF MEDICINE & SCI
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-05-01 至 2023-05-15
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10597534
关键词：
Acceleration Address Affect Age Age Years Alternative Splicing Amino Acid Sequence Animal Model Antisense Oligonucleotides Base Sequence Behavior Biological Assay Biological Markers Biology Blindness Brain C-terminal CLN3 gene Cell model Cells Cessation of life Child Childhood Clinical Trials Cognitive Data Dementia Disease Disease Progression Disease model Dose Ensure Exons Eye Family suidae Functional disorder Genes Goals Health Human Human Cell Line In Vitro Investigational Drugs Label Length Life Life Expectancy Lysosomal Storage Diseases Mediating Messenger RNA Motor Mus Mutate Mutation Nerve Degeneration Neurologic Neurons Open Reading Frames Pathology Patients Pharmacodynamics Production Protein Isoforms Protein Truncation Proteins RNA Splicing Reading Frames Recovery Research Retina Scientist Seizures Spielmeyer-Vogt Disease Symptoms Terminator Codon Testing Therapeutic Therapeutic Effect Tissues Translating Transmembrane Domain Vision autosome cognitive disability disease phenotype early childhood effective therapy human model improved in vitro activity in vivo in vivo monitoring innovation mRNA Precursor mouse model mutant neuropathology new therapeutic target novel novel strategies porcine model preclinical development preclinical efficacy premature protein function standard of care success therapeutic development therapeutic target tool trafficking treatment strategy

项目摘要

CLN3 Batten disease is a fatal lysosomal storage disorder (LSD) resulting from autosomal recessive mutations in CLN3. The disease progresses from vision loss in early childhood to seizures, motor decline, cognitive disability and dementia, with a typical life expectancy of 15-30 years of age. There is no cure for CLN3 Batten and the only treatments available address some disease symptoms, but do not delay disease progression. The discovery of an effective treatment for CLN3 Batten has been hindered by a lack of understanding of the protein's function and the underlying mechanisms leading to neurodegeneration. The goal of this proposal is to test a therapeutic approach for CLN3 Batten that employs antisense oligonucleotides (ASOs) and in so doing, elucidate mechanisms of neurodegeneration in this disease that will inform research and discovery of effective treatments for Batten diseases and other LSDs. Most cases of CLN3 Batten are caused by deletion of exons 7 and 8 (CLN3Δ78), which results in an open reading frame shift and a premature termination codon. We hypothesize that using ASOs to redirect pre-mRNA splicing and correct the reading frame of CLN3Δ78 mRNA will partially restore protein function and have a therapeutic effect in CLN3 Batten disease. Our preliminary findings support our hypothesis, demonstrating that restoring the CLN3Δ78 reading frame alleviates dysfunction associated with disease in both cell and animal models. We will test our hypothesis in the proposed project with the aims to 1) compare the function of the wild type and novel CLN3 isoforms, 2) develop an approach using ASOs to increase CLN3Δex78 isoforms, 3) assess ASO treatments for CLN3 Batten disease using human cell lines as well as mouse and 4) porcine models of CLN3 Batten disease. Collectively, this study will allow us to better understand the function of the CLN3 protein and the utility of ASOs in treating CLN3 Batten disease.

CLN3巴顿病是一种由常染色体隐性突变引起的致命性溶酶体贮积症（LSD）